Baird Maintains Neutral on Sage Therapeutics, Lowers Price Target to $9
Portfolio Pulse from Benzinga Newsdesk
Baird analyst Joel Beatty maintains a Neutral rating on Sage Therapeutics and lowers the price target from $13 to $9.

October 09, 2024 | 11:19 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Baird analyst Joel Beatty has maintained a Neutral rating on Sage Therapeutics while lowering the price target from $13 to $9, indicating a less optimistic outlook.
The reduction in the price target from $13 to $9 by Baird suggests a less favorable view on Sage Therapeutics' future performance, which could lead to a negative short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100